KCNJ11 and diabetes mellitus: Kir6.2 (KCNJ11), SUR1, and SUR2 are overexpressed in the cell lines and biopsies of patients with CC; in addition, when treating the cell lines with glibenclamide (a drug used in the treatment of diabetes that blocks KCNJ11) [188], cell proliferation was inhibited (Table 2) [82].